UPDATE: Brean Murray Carret Raises Target on DexCom to $13.50
Brean Murray Carret maintains its Buy rating on DexCom (NASDAQ: DXCM) and raises its price target $1 to $13.50 a share on on several updates of interest by the company.
Brean Murray Carret says, "Management did firmly communicate its intent to be cash flow positive during 2013 and perhaps as early as late 2012 (our model remains more conservative). The company also confirmed the completion of their Gen4 sensor pivotal trial and will file near term, which we think is slightly ahead of consensus expectations. The small acquisition of a universal data management system vendor, SweetSpot, should also be well received."
DXCM closed at $11.19 a share on Thursday.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.